Concepedia

Eric Assenat

EA

Statistics

Publications

3

Citations

870

H-Index

3

Active since

2017

Affiliations

Inserm(Current)

Hôpital Beaujon

Délégation Paris 5

Centre Hospitalier Universitaire de Montpellier

Université Grenoble Alpes

Eric Assenat is an author at Inserm specializing in medicine, oncology, and hepatocellular carcinoma pharmacotherapy.

Publications per year

2017–2024

3

Publications

3

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial

Valérie Vilgrain, Héléna Pereira, Eric Assenat et al. · The Lancet Oncology · 2017 · 826 citations

Medicine, Oncology, Radiation Oncology +16

Ipilimumab with atezolizumab-bevacizumab in patients with advanced hepatocellular carcinoma: The PRODIGE 81-FFCD 2101-TRIPLET-HCC trial

Philippe Merle, Jean‐Frédéric Blanc, Julien Edeline et al. · Digestive and Liver Disease · 2023 · 22 citations · Full text

Medicine, Oncology, Pharmacology +13

Pemigatinib for patients with previously treated, locally advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements: A joint analysis of the French PEMI-BIL and Italian PEMI-REAL cohort studies

Alessandro Parisi, Blandine Delaunay, Giada Pinterpe et al. · European Journal of Cancer · 2024 · 22 citations · Full text

Medicine, Oncology, Pharmacology +14

1–3 of 3